BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)


| Study or Subgroup | Sacubitril/valsartan Events | Total | Control Events | Total | Weight | Risk Ratio M-H, Random, 95% CI |
|---|---|---|---|---|---|---|
| **1.3.1 Valsartan** | | | | | | |
| CLCZ696B2223 | 0 | 8 | 0 | 8 | | Not estimable |
| PRIME-HF 2019 | 1 | 60 | 0 | 58 | 0.1% | 2.90 [0.12, 69.81] |
| **Subtotal (95% CI)** | | **68** | | **66** | **0.1%** | **2.90 [0.12, 69.81]** |
| Total events | 1 | | 0 | | | |
| Heterogeneity: Not applicable | | | | | | |
| Test for overall effect: Z = 0.66 (P = 0.51) | | | | | | |
| **1.3.2 Enalapril** | | | | | | |
| AWAKE-HF 2019 | 0 | 69 | 1 | 70 | 0.1% | 0.34 [0.01, 8.16] |
| EVALUTE-HF 2019 | 1 | 231 | 1 | 232 | 0.1% | 1.00 [0.06, 15.96] |
| OUTSTEP-HF | 1 | 309 | 4 | 310 | 0.2% | 0.25 [0.03, 2.23] |
| PARADIGM-HF 2014 | 729 | 4203 | 848 | 4229 | 97.9% | 0.86 [0.79, 0.95] |
| PIONEER-HF 2018 | 10 | 440 | 15 | 441 | 1.3% | 0.67 [0.30, 1.47] |
| **Subtotal (95% CI)** | | **5252** | | **5282** | **99.5%** | **0.86 [0.79, 0.94]** |
| Total events | 741 | | 869 | | | |
| Heterogeneity: Tau² = 0.00; Chi² = 1.97, df = 4 (P = 0.74); I² = 0% | | | | | | |
| Test for overall effect: Z = 3.34 (P = 0.0008) | | | | | | |
| **1.3.4 Benazepril** | | | | | | |
| Li J 2019 (1) | 3 | 62 | 5 | 64 | 0.4% | 0.62 [0.15, 2.48] |
| **Subtotal (95% CI)** | | **62** | | **64** | **0.4%** | **0.62 [0.15, 2.48]** |
| Total events | 3 | | 5 | | | |
| Heterogeneity: Not applicable | | | | | | |
| Test for overall effect: Z = 0.68 (P = 0.50) | | | | | | |
| **Total (95% CI)** | | **5382** | | **5412** | **100.0%** | **0.86 [0.79, 0.94]** |
| Total events | 745 | | 874 | | | |
| Heterogeneity: Tau² = 0.00; Chi² = 2.75, df = 6 (P = 0.84); I² = 0% | | | | | | |
| Test for overall effect: Z = 3.36 (P = 0.0008) | | | | | | |
| Test for subgroup differences: Chi² = 0.78, df = 2 (P = 0.68), I² = 0% | | | | | | |